Aylin Sungur
Aylin Sungur has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Fatma Can
Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul 34668, Turkey
4 shared publications - Mustafa Azmi Sungur
SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL DR. SİYAMİ ERSEK GÖĞÜS KALP VE DAMAR CERRAHİSİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, KARDİYOLOJİ ANABİLİM DALI
4 shared publications - Ali Karagöz
Department of Cardiology, Kartal Koşuyolu High Specialization Education and Research Hospital, Istanbul, Türkiye
3 shared publications - Can Yucel Karabay
Cardiology Clinic, Kartal Kosuyolu Heart and Research Hospital, Istanbul, Turkey
3 shared publications - Aycan Esen Zencirci
Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye
2 shared publications - Barış Şimşek
Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, University of Health Sciences, Istanbul 34668, Türkiye
2 shared publications
Latest Publications
- Open Access
Composite Haematological and Nutritional Indices Show No Evidence of Improved Long-Term Mortality Discrimination Beyond Their Own Components in Non-ST-Segment Elevation Myocardial Infarction
Background and Objectives: Composite indices from routine inflammatory, haematological and nutritional measurements are widely reported as prognostic markers after acute coronary syndromes, but whether they add information beyond their components is uncertain. Materials and Methods: In 30-day survivors of non-ST-segment elevation myocardial infarction (NSTEMI) undergoing coronary angiography at a single centre, thirteen composite indices and six prespecified components were evaluated for five-year all-cause mortality using ROC analysis, Cox regression and the change in Harrell’s C-index (ΔC) over a study clinical model. Each index was also compared with a freely weighted model of its own constituents and with a reference model adding CRP and albumin. Results: Among 561 patients (median follow-up 5.48 years), 94 died, 86 within five years. Composite-index AUCs ranged from 0.616 to 0.689; none exceeded CRP alone after multiplicity correction. Eight indices were nominally associated with mortality after adjustment (hazard ratios 1.26–1.38 per 1 SD), but every bootstrap confidence interval for ΔC over the clinical model included zero. Fixed indices and freely weighted constituents performed similarly (cross-validated ΔC −0.0089 to +0.0053), with one small exploratory difference favouring the fixed MLR ratio. Adding CRP and albumin raised the C-index from 0.7720 to 0.7826; over this reference, no estimable composite showed evidence of association (all p ≥ 0.19). Conclusions: In 30-day survivors of NSTEMI, composite indices showed no evidence of improved long-term mortality discrimination over a study-specific clinical model and contained no information beyond their measured constituents. Their independent associations may largely reflect information already present in the components. Small gains cannot be excluded; the findings do not establish equivalence.
Open AccessComposite Haematological and Nutritional Indices Show No Evidence of Improved Long-Term Mortality Discrimination Beyond Their Own Components in Non-ST-Segment Elevation Myocardial Infarction
Background and Objectives: Composite indices from routine inflammatory, haematological and nutritional measurements are widely reported as prognostic markers after acute coronary syndromes, but whether they add information beyond their components is uncertain. Materials and Methods: In 30-day survivors of non-ST-segment elevation myocardial infarction (NSTEMI) undergoing coronary angiography at a single centre, thirteen composite indices and six prespecified components were evaluated for five-year all-cause mortality using ROC analysis, Cox regression and the change in Harrell’s C-index (ΔC) over a study clinical model. Each index was also compared with a freely weighted model of its own constituents and with a reference model adding CRP and albumin. Results: Among 561 patients (median follow-up 5.48 years), 94 died, 86 within five years. Composite-index AUCs ranged from 0.616 to 0.689; none exceeded CRP alone after multiplicity correction. Eight indices were nominally associated with mortality after adjustment (hazard ratios 1.26–1.38 per 1 SD), but every bootstrap confidence interval for ΔC over the clinical model included zero. Fixed indices and freely weighted constituents performed similarly (cross-validated ΔC −0.0089 to +0.0053), with one small exploratory difference favouring the fixed MLR ratio. Adding CRP and albumin raised the C-index from 0.7720 to 0.7826; over this reference, no estimable composite showed evidence of association (all p ≥ 0.19). Conclusions: In 30-day survivors of NSTEMI, composite indices showed no evidence of improved long-term mortality discrimination over a study-specific clinical model and contained no information beyond their measured constituents. Their independent associations may largely reflect information already present in the components. Small gains cannot be excluded; the findings do not establish equivalence.
- Open Access
- 19 July 2023
- Published by Pamukkale University in Pamukkale Medical Journal
Relationship between CONUT score and mortality in patients with pulmonary arterial hypertension
Purpose: Data about the association of malnutrition with prognosis in pulmonary arterial hypertension (PAH) is limited. This study aims to evaluate the relationship of Controlling Nutritional Status (CONUT) score with long-term mortality in PAH. Materials and methods: All consecutive patients newly diagnosed with PAH between 2013 and 2020 were evaluated. CONUT score at diagnosis was calculated through total lymphocyte, albumin and total cholesterol levels. Primary outcome was long-term all-cause mortality. Patients were followed up for 62 (31.3-91.5) months. Results: 92 patients (mean age=43.915.7 years, 65.2% women) were included. 37% of the patients had any degree of malnutrition according to CONUT score (2). Patients without malnutrition were significantly more in the low-risk categories of risk stratification tools (44.8% vs 17.6% according to ESC/ERS guideline, p=0.03; 70.7% vs 35.3% and 70.7% vs 32.4% according to REVEAL 2.0 and REVEAL Lite 2, p
- 19 July 2023
- Published by Pamukkale University in Pamukkale Medical Journal
Open AccessRelationship between CONUT score and mortality in patients with pulmonary arterial hypertension
Purpose: Data about the association of malnutrition with prognosis in pulmonary arterial hypertension (PAH) is limited. This study aims to evaluate the relationship of Controlling Nutritional Status (CONUT) score with long-term mortality in PAH. Materials and methods: All consecutive patients newly diagnosed with PAH between 2013 and 2020 were evaluated. CONUT score at diagnosis was calculated through total lymphocyte, albumin and total cholesterol levels. Primary outcome was long-term all-cause mortality. Patients were followed up for 62 (31.3-91.5) months. Results: 92 patients (mean age=43.915.7 years, 65.2% women) were included. 37% of the patients had any degree of malnutrition according to CONUT score (2). Patients without malnutrition were significantly more in the low-risk categories of risk stratification tools (44.8% vs 17.6% according to ESC/ERS guideline, p=0.03; 70.7% vs 35.3% and 70.7% vs 32.4% according to REVEAL 2.0 and REVEAL Lite 2, p
- 28 June 2023
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 83 (5) , 290-298
Cardiohepatic syndrome and its prognostic predictive ability in patients with pulmonary arterial hypertension
With the development of progressive right ventricular dysfunction, pulmonary arterial hypertension (PAH) is one of the causes of type 2 cardiohepatic syndrome (CHS). Risk assessment, timely and effective management are crucial to improve survival in PAH. Thus, we aimed to evaluate the presence of CHS at diagnosis and its association with prognosis in patients with PAH. One hundred and eighteen consecutive incident patients with PAH between January 2013 and June 2021 were retrospectively included. The presence of CHS was assessed from blood tests taken during diagnostic evaluation and was defined as elevation of at least two of three cholestatic liver parameters; total bilirubin, alkaline phosphatase and gamma-glutamyl transferase. The primary endpoint was all-cause mortality. Patients were followed for a median period of 58 (32-96) months. 23.7% of the patients had CHS at diagnosis. Significantly more patients in CHS (+) group were in intermediate and high-risk categories according to 2015 ESC/ERS guideline, REVEAL 2.0 and REVEAL Lite 2 risk assessment methods (p = .02, .03 and <.001, respectively). The presence of CHS was identified as an independent predictor of mortality (HR: 2.17, 95% CI: 1.03-4.65, p = .03) along with older age (HR: 2.89, 95% CI: 1.50-5.56, p = .001) and higher WHO functional class (HR: 2.57, 95% CI: 1.07-6.22, p = .03). To conclude, presence of CHS at diagnosis in patients with PAH was associated with severe disease and poor prognosis independent of other well known risk factors. As a simple and easy parameter to assess from routinely taken blood tests, CHS should be evaluated in patients with PAH.
- 28 June 2023
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 83 (5) , 290-298
Cardiohepatic syndrome and its prognostic predictive ability in patients with pulmonary arterial hypertension
With the development of progressive right ventricular dysfunction, pulmonary arterial hypertension (PAH) is one of the causes of type 2 cardiohepatic syndrome (CHS). Risk assessment, timely and effective management are crucial to improve survival in PAH. Thus, we aimed to evaluate the presence of CHS at diagnosis and its association with prognosis in patients with PAH. One hundred and eighteen consecutive incident patients with PAH between January 2013 and June 2021 were retrospectively included. The presence of CHS was assessed from blood tests taken during diagnostic evaluation and was defined as elevation of at least two of three cholestatic liver parameters; total bilirubin, alkaline phosphatase and gamma-glutamyl transferase. The primary endpoint was all-cause mortality. Patients were followed for a median period of 58 (32-96) months. 23.7% of the patients had CHS at diagnosis. Significantly more patients in CHS (+) group were in intermediate and high-risk categories according to 2015 ESC/ERS guideline, REVEAL 2.0 and REVEAL Lite 2 risk assessment methods (p = .02, .03 and <.001, respectively). The presence of CHS was identified as an independent predictor of mortality (HR: 2.17, 95% CI: 1.03-4.65, p = .03) along with older age (HR: 2.89, 95% CI: 1.50-5.56, p = .001) and higher WHO functional class (HR: 2.57, 95% CI: 1.07-6.22, p = .03). To conclude, presence of CHS at diagnosis in patients with PAH was associated with severe disease and poor prognosis independent of other well known risk factors. As a simple and easy parameter to assess from routinely taken blood tests, CHS should be evaluated in patients with PAH.
- Open Access
- 1 January 2023
- Published by Kare Publishing in Northern Clinics of Istanbul
- Vol. 10 (5) , 567-574
Body fat percentage and infarct size in patients with non-ST segment elevation myocardial infarction
Obesity is a global health problem that increases the risk of coronary artery disease (CAD). However in studies, it has been observed that when the disease develops, obese patients have a more favorable prognosis than leaner patients. This is called the “obesity paradox.” This study aims to evaluate the effect of obesity assessed with body fat percentage (BFP) and relative fat mass (RFM) besides body mass index (BMI) on infarct size (IS) estimated from peak creatine kinase-MB (CK-MB) levels in patients with non-ST-segment elevation myocardial infarction (NSTEMI). Patients with a diagnosis of NSTEMI who underwent coronary angiography between January 2017 and January 2022 were retrospectively evaluated. Patients without available anthropometric data to calculate BMI, BFP, and RFM and serial CK-MB measurements were excluded from the study. BMI was calculated using weight(kg)/(height[m])2 formula. Patients were dichotomized as obese (BMI≥30 kg/m2) and non-obese (BMI2) to compare baseline characteristics. BFP and RFM were calculated from anthropometric data. Linear regression analysis was performed to define predictors of IS. Final study population consisted of 748 NSTEMI patients (mean age was 59.3±11.2 years, 76.3% were men, 36.1% of the patients were obese). Obese patients were more likely to be female, hypertensive, and diabetic. Smoking was less frequently observed in obese patients. Peak CK-MB levels were similar among groups. Obese patients had higher in-hospital left ventricular ejection fraction, and less severe CAD was observed in coronary angiographies of these patients. Multivariable regression analysis identified diabetes mellitus, systolic blood pressure, white blood cell count, hemoglobin, and BFP (β=-4.8, 95% CI=-8.7; -0.3, p=0.03) as independent predictors of IS. Higher BFP is associated with smaller IS in NSTEMI patients. These findings support the obesity paradox in this patient group, but further, randomized controlled studies are required.
- 1 January 2023
- Published by Kare Publishing in Northern Clinics of Istanbul
- Vol. 10 (5) , 567-574
Open AccessBody fat percentage and infarct size in patients with non-ST segment elevation myocardial infarction
Obesity is a global health problem that increases the risk of coronary artery disease (CAD). However in studies, it has been observed that when the disease develops, obese patients have a more favorable prognosis than leaner patients. This is called the “obesity paradox.” This study aims to evaluate the effect of obesity assessed with body fat percentage (BFP) and relative fat mass (RFM) besides body mass index (BMI) on infarct size (IS) estimated from peak creatine kinase-MB (CK-MB) levels in patients with non-ST-segment elevation myocardial infarction (NSTEMI). Patients with a diagnosis of NSTEMI who underwent coronary angiography between January 2017 and January 2022 were retrospectively evaluated. Patients without available anthropometric data to calculate BMI, BFP, and RFM and serial CK-MB measurements were excluded from the study. BMI was calculated using weight(kg)/(height[m])2 formula. Patients were dichotomized as obese (BMI≥30 kg/m2) and non-obese (BMI2) to compare baseline characteristics. BFP and RFM were calculated from anthropometric data. Linear regression analysis was performed to define predictors of IS. Final study population consisted of 748 NSTEMI patients (mean age was 59.3±11.2 years, 76.3% were men, 36.1% of the patients were obese). Obese patients were more likely to be female, hypertensive, and diabetic. Smoking was less frequently observed in obese patients. Peak CK-MB levels were similar among groups. Obese patients had higher in-hospital left ventricular ejection fraction, and less severe CAD was observed in coronary angiographies of these patients. Multivariable regression analysis identified diabetes mellitus, systolic blood pressure, white blood cell count, hemoglobin, and BFP (β=-4.8, 95% CI=-8.7; -0.3, p=0.03) as independent predictors of IS. Higher BFP is associated with smaller IS in NSTEMI patients. These findings support the obesity paradox in this patient group, but further, randomized controlled studies are required.
- 1 January 2023
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 17 (2) , 111-121
Prognostic Impact of Cardiohepatic Syndrome in Patients with St-Segment Elevation Myocardial Infarction
Background: Cardiohepatic syndrome (CHS) indicates a bidirectional interaction between the heart and liver. This study was designed to evaluate the impact of CHS on in-hospital and long-term mortal...
- 1 January 2023
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 17 (2) , 111-121
Prognostic Impact of Cardiohepatic Syndrome in Patients with St-Segment Elevation Myocardial Infarction
Background: Cardiohepatic syndrome (CHS) indicates a bidirectional interaction between the heart and liver. This study was designed to evaluate the impact of CHS on in-hospital and long-term mortal...
- 3 May 2022
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 44 (5) , 487-494
Effects of RAAS blocker use on AKI in elderly hypertensive STEMI patients with propensity score weighed method
Studies reported conflicting results on the effect of renin-angiotensin-aldosterone system (RAAS) blocker use on acute kidney injury (AKI) in patients undergoing elective coronary angiography but association in elderly patients with ST-elevation myocardial infarction (STEMI) is not known. Also, there are limited data on the effect of inflammatory markers on AKI. We aimed to investigate the effects of RAAS blocker pretreatment and inflammatory markers on AKI in this population. A total of 471 patients were compared according to presence of RAAS blocker pretreatment at admission. Conventional and inverse probability weighed conditional logistic regression were used to determine independent predictors of AKI. Mean age of the study group was 75.4 ± 7.1 years and 29.1% of the patients were female. AKI was observed in 17.2% of the study population. Weighted conditional multivariable logistic regression analysis revealed that AKI was associated with baseline creatinine levels and C-reactive protein/albumin ratio (CAR) (OR 2.08, 95% CI = 1.13–3.82, p = .02 and OR 1.19, 95% CI = 1.01–1.41, p = .04, respectively). No significant association was found between RAAS blocker pretreatment and AKI. CAR and elevated baseline creatinine levels were independent predictors of AKI in this patient group.
- 3 May 2022
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 44 (5) , 487-494
Effects of RAAS blocker use on AKI in elderly hypertensive STEMI patients with propensity score weighed method
Studies reported conflicting results on the effect of renin-angiotensin-aldosterone system (RAAS) blocker use on acute kidney injury (AKI) in patients undergoing elective coronary angiography but association in elderly patients with ST-elevation myocardial infarction (STEMI) is not known. Also, there are limited data on the effect of inflammatory markers on AKI. We aimed to investigate the effects of RAAS blocker pretreatment and inflammatory markers on AKI in this population. A total of 471 patients were compared according to presence of RAAS blocker pretreatment at admission. Conventional and inverse probability weighed conditional logistic regression were used to determine independent predictors of AKI. Mean age of the study group was 75.4 ± 7.1 years and 29.1% of the patients were female. AKI was observed in 17.2% of the study population. Weighted conditional multivariable logistic regression analysis revealed that AKI was associated with baseline creatinine levels and C-reactive protein/albumin ratio (CAR) (OR 2.08, 95% CI = 1.13–3.82, p = .02 and OR 1.19, 95% CI = 1.01–1.41, p = .04, respectively). No significant association was found between RAAS blocker pretreatment and AKI. CAR and elevated baseline creatinine levels were independent predictors of AKI in this patient group.
- 25 December 2021
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (5) , 1007-1013
Peritoneal dialysis for refractory heart failure: A single‐center experience
Introduction: Heart failure (HF) is a disease associated with poor quality of life. Peritoneal dialysis (PD) can be an alternative in the treatment of these patients to overcome fluid overload. The objective of this study is to observe the effects of PD in refractory HF patients.Methods: We conducted an observational study including 10 patients with refractory congestive HF. PD started solely for fluid overload. Patients' baseline parameters were compared with follow‐up parameters.Results: Median age was 57.5 (44.8–64.3) years. Median left ventricular ejection fraction was 20% (18.8–31.3), and all patients had right ventricular dysfunction. Median estimated glomerular filtration rate was 51.2 (43.8–101.3) ml/min/1.73 m2. Two patients (20%) died during the follow‐up period. New York Heart Association (NYHA) functional class decreased significantly from a median of 4 to 2,1 and 1 in the 3rd, 6th, and 12th months, respectively (p ≤ 0.01 for all from baseline). Number and length of hospitalization decreased significantly after treatment (number from a median of 3 to 0,p = 0.013; days from 50.5 to 0,p = 0.028).Conclusion: PD significantly reduced NYHA functional class, number and days of hospitalization for HF. It could be a reasonable option in chronic treatment of patients with refractory HF.
- 25 December 2021
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (5) , 1007-1013
Peritoneal dialysis for refractory heart failure: A single‐center experience
Introduction: Heart failure (HF) is a disease associated with poor quality of life. Peritoneal dialysis (PD) can be an alternative in the treatment of these patients to overcome fluid overload. The objective of this study is to observe the effects of PD in refractory HF patients.Methods: We conducted an observational study including 10 patients with refractory congestive HF. PD started solely for fluid overload. Patients' baseline parameters were compared with follow‐up parameters.Results: Median age was 57.5 (44.8–64.3) years. Median left ventricular ejection fraction was 20% (18.8–31.3), and all patients had right ventricular dysfunction. Median estimated glomerular filtration rate was 51.2 (43.8–101.3) ml/min/1.73 m2. Two patients (20%) died during the follow‐up period. New York Heart Association (NYHA) functional class decreased significantly from a median of 4 to 2,1 and 1 in the 3rd, 6th, and 12th months, respectively (p ≤ 0.01 for all from baseline). Number and length of hospitalization decreased significantly after treatment (number from a median of 3 to 0,p = 0.013; days from 50.5 to 0,p = 0.028).Conclusion: PD significantly reduced NYHA functional class, number and days of hospitalization for HF. It could be a reasonable option in chronic treatment of patients with refractory HF.